Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Invasive Bladder Urothelial Carcinoma Clear all
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
Interventions
BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Bladder Cancer
Interventions
Gemcitabine, Docetaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
12
States / cities
Phoenix, Arizona • Stanford, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions
NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Drug · Other
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
Interventions
CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma Bladder
Interventions
Not listed
Lead sponsor
Pangea Laboratory LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced May 22, 2026, 1:30 AM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Drug · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Intravesical BCG and EMDA/MMC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions
PF-07329640, sasanlimab, bevacizumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
Interventions
Vicinium
Drug
Lead sponsor
Sesen Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Tallahassee, Florida • Baltimore, Maryland • Lawrenceville, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Superficial Bladder Urothelial Carcinoma
Interventions
Acupuncture Therapy, BCG Solution, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Device · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced May 22, 2026, 1:30 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Bladder Tumor, Urothelial Carcinoma
Interventions
Sulforaphane Administration, Placebo Administration, Standard of Care Surgery
Drug · Other · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2039
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
PD-L1/IDO Peptide Vaccine, Pembrolizumab
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Internet-Based Intervention, Best Practice, Exercise Intervention, Health Telemonitoring, Educational Intervention, Questionnaire Administration, Interview, Electronic Health Record Review
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
VAX014
Drug
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Edison, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced May 22, 2026, 1:30 AM EDT